Parapsoriasis en plaques is a chronic and inflammatory skin disorder that belongs to a group of conditions known as cutaneous T-cell lymphoproliferative disorders (CTCL). It is characterized by the presence of scaly, erythematous, flat patches or plaques on the skin. The condition primarily affects adults and typically appears after the age of 40.
The exact cause of parapsoriasis en plaques is not fully understood, but it is believed to involve an abnormal immune response. It is speculated that it may arise from the proliferation of abnormal T-cells, which are a type of white blood cell involved in the immune response. However, the condition is distinct from lymphoma, as it tends to have a more benign course.
Common symptoms of parapsoriasis en plaques include the development of reddish or salmon-colored patches on the trunk, limbs, or other areas of the body. These patches may be slightly elevated and covered with fine scales. Itching may also be present but is usually mild. The condition can persist for years or even decades, with periods of exacerbation and remission.
The diagnosis of parapsoriasis en plaques is based on clinical examination, medical history, and the characteristic pattern of the skin lesions. In some cases, a skin biopsy may be performed to confirm the diagnosis and rule out similar skin conditions or lymphomas.
Treatment for parapsoriasis en plaques often involves the use of topical corticosteroids to reduce inflammation and alleviate itching. Phototherapy, which involves controlled exposure to ultraviolet light, may also be beneficial. In severe cases, systemic therapy with medications such as retinoids, methotrexate, or photopheresis may be recommended. Regular monitoring is essential to ensure early detection of any potential progression to lymphoma
